Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06091514
Other study ID # APHP230642
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date February 2026

Study information

Verified date October 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Gilles MONTALESCOT, Prof
Phone 0142163007
Email gilles.montalescot@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

New-onset of atrial fibrillation (AF) and atrial arrythmia (AA) in general, is important as it exposes patients to stroke or other embolic complications not to mention the risk of heart failure. AF detection in high risk populations such as patients with a recent stroke or TIA or, symptomatic patients with multiple risk factors for AF, is performed with long-term electrocardiography monitoring using frequently implantable loop recorders (ILR). These recorders have their own limitations related to the invasive nature of the device implanted under the skin of the chest with limited acceptation by the patients. Smart watches appear as useful alternatives, but they need to be evaluated in an all-comer population of patients highly exposed to AF, different from the large population studies conducted in healthy young adults with a low incidence of AF. The unique features of CardiacSense Medical System suggest that we could have an accurate noninvasive detection of AF in a selected population very much exposed to the risk of atrial fibrillation, the most frequent atrial arrhythmia.


Description:

Study design : This clinical investigation is a comparative, non-randomised, one group, controlled study. Each patient represents its own control. The study will envolve 400 participants Hypothesis : Our hypothesis is that CardiacSense Medical System is an effective, safe, and better accepted alternative for detecting atrial fibrillation (AF) in a high-risk population than implantable loop recorders (ILRs). Population : Any patient aged 18 years or more, with an ILR implanted for the detection of AF will be eligible. The time of implantation will not matter as long as the batteries work. Each patient will be proposed a CS Medical Watch for a period corresponding to the period at risk of AF. Main objective : To compare the performance of the CardiacSense Medical Watch by pulse plethysmography (PPG) only to the gold standard method of ILR monitoring, to detect AF that lasts 5 minutes or more, in a population of patients at high risk of paroxysmal AF.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 400
Est. completion date February 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient aged 18 years or more - Patient having signed free, informed, and written consent - Patient presenting one of the following situations : - Post-stroke or TIA patient with an already in place ILR - Patient with symptoms evocative of AF (e.g. increased heart rate, chest pain) with an already in place ILR - Post-PFO closure patient with an already in place ILR - Patient in sinus rhythm treated for the prevention of paroxysmal AF with an already in place ILR - Patient at high risk of AF (at the discretion of the investigator) with an already in place ILR - Patient with a period of risk of AF = 3 months. Exclusion Criteria: - Patient under legal protection - Pregnant and/or breastfeeding women - Patient with pacemakers, or ICD - Patient with blood flow deficiency-related conditions - Patient with tattoo or injured skin on the wrist - Patient with tremors or otherwise unable to remain still for 15 minutes - Patient without two hands and sufficient fingers to complete the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CS Medical Watch
The Use of the CS Medical Watch during the participation period of the clinical investigation (between 3 and 12 months according to the period at risk of AF).
Other:
Specific questionnaire
Specific questionnaire during the last study visit (takes place at M3 to M12 according to the period at risk of AF)

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Action Research Group, Hôpital Lariboisière Fernand Widal

Outcome

Type Measure Description Time frame Safety issue
Primary The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring using the CardiacSense Medical Watch by pulse plethysmography (PPG) only vs the gold standard method of ILR ECG recording, over the same period of monitoring by the two devices for each patient. between 3 and 12 months according to the period at risk of AF
Secondary The total number of AA episodes that lasts 5 min or more recorded on long-term monitoring The total number of AA episodes that lasts 5 min or more detected by PPG and confirmed by ECG measurement of the CardiacSense Medical Watch (vs. ILR ECG recording) over the same period of monitoring by the two devices for each patient. between 3 and 12 months according to the period at risk of AF
Secondary The total number of episodes AF that lasts 5 min or more recorded on long-term monitoring Same primary endpoint for symptomatic patients vs. asymptomatic patients between 3 and 12 months according to the period at risk of AF
Secondary The total duration of AF episodes that lasts 5 min or more Total duration of AF episodes that lasts 5 min or more / total duration of monitoring expressed in % for each device (PPG CS watch only vs. ILR ECG recording). between 3 and 12 months according to the period at risk of AF
Secondary Incidence and severity of CS device vs ILR devices Related Adverse Events and incidents during the patient participation between 3 and 12 months according to the period at risk of AF
Secondary Degree of invasiveness, comfort, and ease of use of both devices Description : measured using specific questionnaires for the study between 3 and 12 months according to the period at risk of AF
Secondary Medico-economic evaluation according to the AP-HP hospital costs The cost of each medical device (considering the replacement when needed over the study period for each patient)
The cost for extra-consultation/hospitalization for surgery, complication, or education.
between 3 and 12 months according to the period at risk of AF
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A